Granite Bio raises €27.0M Series A round
24 April 2025· Basel, Switzerland· health, immunology, biotech, antibodies, therapeutics, b2b
The funding will be used to advance Granite Bio's two therapeutic antibodies, GRT-001 and GRT-002, targeting multiple autoimmune diseases. GRT-001 is in Phase 1a testing and expected to enter Phase 1b, while GRT-002 is in preclinical development and expected to enter clinical trials in 2026.
Investors
LeadVersant Ventures
Also participating
Novartis Venture Fund
About Granite Bio
Stage
Series B
Headquarters
Basel, Switzerland
Founded
2021
Team Size
21–50
Sectors
healthimmunologybiotechantibodiestherapeuticsb2b